Validation of the multiple sclerosis international quality of life (MusiQoL) questionnaire in Norwegian patients

Authors


A. G. Beiske, Department of Neurology, Akershus University Hospital, Akershus, Lørenskog N 1478, Norway
Tel.: +47 9013 9337
Fax: +47 6796 8861
e-mail: agbeiske@gmail.com

Abstract

Beiske AG, Baumstarck K, Nilsen RM, Simeoni M-C. Validation of the multiple sclerosis international quality of life (MusiQoL) questionnaire in Norwegian patients.
Acta Neurol Scand: 2012: 125: 171–179.
© 2011 John Wiley & Sons A/S.

Objectives –  To assess the validity and reliability of the multidimensional, self-administered Multiple Sclerosis International Quality of Life (MusiQoL) questionnaire, previously validated in a large international sample, in Norwegian patients.

Patients and methods –  Patients with different types and severities of multiple sclerosis (MS) were recruited from a single MS centre in Norway. All patients completed the MusiQoL and Short Form-36 (SF-36) QoL questionnaires at baseline and a mean of 21 (SD 7) days later. A neurologist collected sociodemographic, MS history and outcome data. Construct validity, internal consistency, reproducibility and external consistency were tested.

Results –  One hundred and four patients were evaluated. Construct validity was confirmed in terms of satisfactory item internal consistency correlations in eight of nine MusiQoL dimensions (Spearman’s correlation: 0.34–0.79) and scaling success of item discriminant validity (75.0–100%). All dimensions of the MusiQoL questionnaire exhibited satisfactory internal consistency (Cronbach’s alpha: 0.44–0.87) and reproducibility (intraclass correlation coefficients: 0.36–0.86). External validity testing showed that the global MusiQoL score correlated significantly with all but one individual SF-36 dimension score (Spearman’s correlation: 0.29–0.56).

Conclusions –  These results demonstrate that the Norwegian-language version of the MusiQoL questionnaire is a valid and reliable instrument for assessing health-related QoL in Norwegian patients with MS.

Ancillary